In its quarterly drug pipeline trends report, OptumRx projected that 2020 will see large numbers of drug approvals for oncology drugs and identified 11 drugs with the potential to be blockbusters in the United States. OptumRx, which is owned by UnitedHealth Group, sorted the drugs likely to be approved this year into 17 treatment categories. Cancer-treating drugs were by far the most prevalent, with 44 likely approvals. Neurology followed with 29.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.